推薦產品
等級
pharmaceutical primary standard
API 家族
rivastigmine
製造商／商標名
EDQM
應用
pharmaceutical (small molecule)
格式
neat
儲存溫度
2-8°C
InChI
1S/C14H22N2O2.C4H6O6/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4;5-1(3(7)8)2(6)4(9)10/h7-11H,6H2,1-5H3;1-2,5-6H,(H,7,8)(H,9,10)/t11-;1-,2-/m00/s1
InChI 密鑰
GWHQHAUAXRMMOT-RWALOXMOSA-N
尋找類似的產品？ 前往 產品比較指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Rivastigmine hydrogen tartrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化／生理作用
卡巴拉汀是一种口服口服、脑透过性、可逆的胆碱酯酶抑制剂，可增强阿尔茨海默症和帕金森氏病患者的认知功能。卡巴拉汀可同时抑制丁酰胆碱酯酶和乙酰胆碱酯酶。
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
相關產品
產品號碼
描述
訂價
訊號詞
Danger
危險聲明
危險分類
Acute Tox. 2 Oral - Aquatic Chronic 2
儲存類別代碼
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Cassandra Richardson et al.
International journal of geriatric psychiatry, 28(12), 1312-1317 (2013-04-16)
A potential anti-inflammatory role for acetylcholinesterase inhibitors (AChEIs) has been supported by animal studies. As very limited data exist from individuals with Alzheimer's disease (AD), the aim of this study was to assess the potential influence of AChEIs on blood
Zhen-Zhen Yang et al.
International journal of pharmaceutics, 452(1-2), 344-354 (2013-05-18)
Alzheimer's disease (AD) is a common progressive neurodegenerative disorder associated with cholinergic neurons degeneration. The blood-brain barrier (BBB) not only provides protection for the brain but also hinders the treatment and diagnosis of this neurological disease, because the drugs must
George Grossberg et al.
American journal of Alzheimer's disease and other dementias, 28(6), 583-591 (2013-08-29)
Stabilizing/reducing decline in the ability to perform activities of daily living (ADLs) is important in management of Alzheimer's disease (AD). Post hoc analysis of OPtimizing Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA), a double-blind trial comparing 13.3 and 9.5 mg/24
Monica Passananti et al.
Water research, 47(14), 5422-5430 (2013-07-19)
In this paper we investigated the degradation of the rivastigmine drug induced by hydroxyl radical in synthetic and natural waters focusing on both reactivity and photoproducts identification. The hydroxyl radical formation rate was quantified by using terephthalic acid as trapping
Atrial flutter in a patient with Alzheimer dementia treated by rivastigmine.
Yi-Chien Hsu et al.
The Journal of neuropsychiatry and clinical neurosciences, 25(2), E25-E26 (2013-05-21)
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務